Evaluation of serum alkaline phosphatase as a marker of metastasis in early breast cancer

2020 ◽  
Vol 33 (2) ◽  
pp. 45-49
Author(s):  
Islam H. Metwally ◽  
Mohamed Zuhdy ◽  
Omar Hamdy ◽  
Mohamed Ezzat ◽  
Mansour Elmoatasem ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Alkaline Phosphatase ◽  
Early Breast Cancer ◽  
Serum Alkaline Phosphatase

First repeated bone scan in the observation of patients with operable breast cancer.

1986 ◽  
Vol 4 (3) ◽  
pp. 389-394 ◽  
Author(s):  
A Pedrazzini ◽  
R Gelber ◽  
M Isley ◽  
M Castiglione ◽  
A Goldhirsch
Keyword(s):  
Breast Cancer ◽  
Alkaline Phosphatase ◽  
Bone Scan ◽  
Serum Alkaline Phosphatase ◽  
Clinical Situation ◽  
Operable Breast Cancer ◽  
First Relapse ◽  
Bone Scans ◽  
First Recurrence

Data on 1,601 patients with node-positive operable breast cancer who were randomized in four different prospective adjuvant therapy trials were analyzed to evaluate the role of routine bone scans and the alkaline phosphatase value at regular intervals in screening for bone involvement. Bone scan was a prerequisite for randomization and was repeated within the first 12 months in 90% (1,441) of the patients. Abnormal or doubtful scan findings had to be verified by x-ray examination. The repeated scan results were normal in 1,263 (87.8%) patients, doubtful but with no radiologic evidence of bone metastasis in 161 (11%), and abnormal (radiologically confirmed) in 17 (1.2%). After a median observation of 4 years bone metastases as the first relapse developed in 136 (8.5%) patients. This occurred in 87 of 1,263 (6.9%) of the patients with normal repeated scan results and in 18 of 161 (11.2%) of those with doubtful repeated scan findings. Based on the results of the first repeated scan, early detection of a first recurrence in bone might have been possible for 2.4% of the population. Serum alkaline phosphatase levels were also without clinical use. Bone scan in the observation of patients with operable breast cancer should be performed only as dictated by the clinical situation.

Comparison between CEA, TPA, CA 15/3 and Hydroxyproline, Alkaline Phosphatase, Whole Body Retention of 99mTc MDP in the follow-up of Bone Metastases in Breast Cancer

1990 ◽  
Vol 5 (2) ◽  
pp. 65-72 ◽  
Author(s):  
G. Francini ◽  
M. Montagnani ◽  
R. Petrioli ◽  
P. Paffetti ◽  
S. Marsili ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Alkaline Phosphatase ◽  
Bone Metastases ◽  
Serum Alkaline Phosphatase ◽  
Whole Body ◽  
Lower Sensitivity ◽  
Osteoblastic Activity ◽  
Body Retention ◽  
Hydroxyproline Excretion

The development of bone metastases in cancer can be monitored easily using three markers: 24 h urinary hydroxyproline excretion (HOP) (an index of osteoclastic activity), serum alkaline phosphatase (Alk.Ph.) (an index of osteoblastic activity) and 24 h whole body retention of 99mTc-methylene diphosphonate (WBR%) (an index of bone turnover). To evaluate the effectiveness of this group of bone tumor markers in breast cancer we compared it with the following group of three markers which are commonly used in the monitoring of breast cancer and in the follow-up of advanced disease with or without bone metastases: carcinoembryonic antigen (CEA), tissue polypeptide antigen (TPA) and breast carcinoma antigen (CA 15/3). In 48 patients with bone metastases CEA, TPA and CA 15/3 were shown to be sensitive (79%, 85%, 90% respectively), while HOP, Alk.Ph. and WBR%, which are commonly accepted as reliable markers of bone activity, showed a lower sensitivity (67%, 46%, 75% respectively). These results may be explained by the lack of osteoclastic or osteoblastic (or both) activity at the time of diagnosis. This explanation is supported by the fact that the bone markers HOP, Alk.Ph. and WBR% were found to be more sensitive than the others in the subsequent follow-up study. We conclude that in our study, CEA, TPA and CA 15/3 are at first more sensitive than Alk. Ph., HOP and WBR% but during the follow-up Alk.Ph., HOP and WBR% are possibly both more specific and more sensitive

scholarly journals Serum Alkaline Phosphatase as a Predictive Marker for Bone Metastasis in Breast Cancer Patients Seen in a Tertiary Health Institution in Northern Nigeria

2020 ◽  
Vol 1 (2) ◽  
Author(s):  
Usman Malami Aliyu ◽  
Musa Ali-Gombe
Keyword(s):  
Breast Cancer ◽  
Alkaline Phosphatase ◽  
Bone Metastases ◽  
Cancer Patients ◽  
Teaching Hospital ◽  
Serum Alkaline Phosphatase ◽  
Metastatic Breast ◽  
Predictive Marker ◽  
University Teaching ◽  
Breast Cancer Patients

Introduction: Early detection of bone metastases is helpful in the treatment of breast cancer. Change in serum levels of alkaline phosphatase could assist diagnosis and follow-up of metastatic breast cancer. Aim: This study aimed to determine the clinical correlates of serum alkaline phosphatase (ALP) levels in breast cancer patients with bone metastases seen in the Department of Radiotherapy and Oncology, Usmanu Danfodiyo University Teaching Hospital, Sokoto, Nigeria. Material and Methods: All breast cancer patients’ case note seen at the department of Radiotherapy and Oncology Usmanu Danfodiyo University Teaching Hospital, Sokoto from January 2012 to January 2017 were retrieved. The Information extracted include age, pre-treatment serum ALP, presence or absence of met

Biochemical markers for detecting bone metastases in patients with breast cancer

1993 ◽  
Vol 39 (1) ◽  
pp. 131-134 ◽  
Author(s):  
L Moro ◽  
C Gazzarrini ◽  
D Crivellari ◽  
E Galligioni ◽  
R Talamini ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Alkaline Phosphatase ◽  
Statistical Analysis ◽  
Bone Resorption ◽  
Bone Metastases ◽  
Biochemical Markers ◽  
Bone Markers ◽  
Serum Alkaline Phosphatase ◽  
Highly Sensitive ◽  
Biochemical Bone Markers

Abstract A study was carried out to assess the best use of biochemical bone markers to exclude metastases in patients with breast cancer. Urinary galactosyl-hydroxylysine and serum alkaline phosphatase were used to monitor bone resorption and deposition, respectively. Hydroxyproline was also measured. In a selected population of patients, possibly affected by metastases on the basis of scintigraphic examination, which is highly sensitive but poorly specific, we assessed the efficiency of the markers by a double statistical analysis. In this group, the only marker able to predict metastases was galactosyl-hydroxylysine.

Sign in / Sign up

Export Citation Format

Share Document